Lee et al., 2016 - Google Patents
Synthesis and evaluation of 6-(3-[18F] fluoro-2-hydroxypropyl)-substituted 2-pyridylbenzothiophenes and 2-pyridylbenzothiazoles as potential PET tracers for imaging …Lee et al., 2016
View PDF- Document ID
- 9725171843683128428
- Author
- Lee B
- Chu S
- Kwon H
- Park C
- Sirion U
- Brockschnieder D
- Dyrks T
- Oh S
- Kim J
- Chi D
- Publication year
- Publication venue
- Bioorganic & Medicinal Chemistry
External Links
Snippet
[18 F] Fluoro-2-hydroxypropyl substituted compounds were synthesized and evaluated as novel 18 F-labeled PET tracers for imaging Aβ plaque in a living brain. All compounds exhibited high binding affinities toward the synthetic Aβ 1–42 aggregate and/or Alzheimer's …
- -1 6-(3-[18F] fluoro-2-hydroxypropyl)-substituted 2-pyridylbenzothiophenes 0 title abstract description 36
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0476—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds; Labelled organic compounds per se
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2318366T3 (en) | PSMA BINDING MATERIALS AND APPLICATIONS THEREOF | |
| JP6216421B2 (en) | Compositions, methods and systems for the synthesis and use of contrast agents | |
| Ono et al. | Novel chalcones as probes for in vivo imaging of β-amyloid plaques in Alzheimer’s brains | |
| Lee et al. | Synthesis and evaluation of 6-(3-[18F] fluoro-2-hydroxypropyl)-substituted 2-pyridylbenzothiophenes and 2-pyridylbenzothiazoles as potential PET tracers for imaging Aβ plaques | |
| JP2011529929A (en) | DAA-pyridine as a ligand for peripheral benzodiazepine receptors for diagnostic imaging and pharmaceutical treatment | |
| Tago et al. | Preclinical evaluation of [18F] THK-5105 enantiomers: effects of chirality on its effectiveness as a tau imaging radiotracer | |
| Pichika et al. | Nicotinic α4β2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F] fluoro-3-[2-((S)-3-pyrrolinyl) methoxy] pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate | |
| KR20100075547A (en) | Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors | |
| Fuchigami et al. | Synthesis and evaluation of ethyleneoxylated and allyloxylated chalcone derivatives for imaging of amyloid β plaques by SPECT | |
| Bouhlel et al. | Synthesis, radiolabeling, and biological evaluation of (R)-and (S)-2-amino-5-[18F] fluoro-2-methylpentanoic acid ((R)-,(S)-[18F] FAMPe) as potential positron emission tomography tracers for brain tumors | |
| JP2012511526A (en) | Benzothiazole amide for detecting amyloid beta | |
| US8378109B2 (en) | Labeled ALPHA4BETA2 ligands and methods therefor | |
| Huang et al. | Radiosynthesis and biological evaluation of alpha-[F-18] fluoromethyl phenylalanine for brain tumor imaging | |
| Zheng et al. | Syntheses and evaluation of fluorinated benzothiazole anilines as potential tracers for β-amyloid plaques in Alzheimer's disease | |
| JP5954737B2 (en) | Radioactive fluorine-labeled quinoxaline compound | |
| Neumaier et al. | Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease | |
| Gündel et al. | Development and evaluation of deuterated [18F] JHU94620 isotopologues for the non-invasive assessment of the cannabinoid type 2 receptor in brain | |
| Zhu et al. | An improved preparation of [18F] FPBM: a potential serotonin transporter (SERT) imaging agent | |
| Pithia et al. | Synthesis and evaluation of (S)-[18F] fesetron in the rat brain as a potential PET imaging agent for serotonin 5-HT3 receptors | |
| Yousefi et al. | Development of an improved radioiodinated 2-phenylimidazo [1, 2-a] pyridine for non-invasive imaging of amyloid plaques | |
| Fu et al. | Synthesis and biological evaluation of 18F-labled 2-phenylindole derivatives as PET imaging probes for β-amyloid plaques | |
| Shalgunov et al. | Synthesis and evaluation in rats of homologous series of [18F]-labeled dopamine D2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers | |
| Jia et al. | Discovery of diphenoxy derivatives with flexible linkers as ligands for β-amyloid plaques | |
| US9029557B2 (en) | Labeled A4B2 ligands and methods therefor | |
| Pichika et al. | Nicotinic α4β2 receptor imaging agents. Part III. Synthesis and biological evaluation of 3-(2-(S)-azetidinylmethoxy)-5-(3′-18F-fluoropropyl) pyridine (18F-nifzetidine) |